---
title: "Tonix Pharma | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.998 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252552303.md"
published_at: "2025-08-11T20:48:52.000Z"
---

# Tonix Pharma | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 1.998 M

Revenue: As of FY2025 Q2, the actual value is USD 1.998 M, missing the estimate of USD 2.433 M.

EPS: As of FY2025 Q2, the actual value is USD -3.86, missing the estimate of USD -2.92.

EBIT: As of FY2025 Q2, the actual value is USD -28.3 M.

### Segment Revenue

-   **Product Revenue, Net**: For the three months ended June 30, 2025, product revenue was $1.998 million, compared to $2.208 million for the same period in 2024. For the six months ended June 30, 2025, product revenue was $4.427 million, compared to $4.690 million in 2024.

### Operational Metrics

-   **Operating Loss**: For the three months ended June 30, 2025, the operating loss was - $28.296 million, compared to - $77.316 million for the same period in 2024. For the six months ended June 30, 2025, the operating loss was - $44.350 million, compared to - $98.667 million in 2024.
-   **Net Loss**: For the three months ended June 30, 2025, the net loss was - $28.272 million, compared to - $78.776 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $45.101 million, compared to - $93.715 million in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was - $31.412 million, compared to - $27.494 million in 2024.
-   **Net Cash Provided by Financing Activities**: For the six months ended June 30, 2025, net cash provided by financing activities was $60.526 million, compared to $6.813 million in 2024.

### Unique Metrics

-   **Grant Income**: For the three months ended June 30, 2025, grant income was $1.036 million, compared to $0 in 2024. For the six months ended June 30, 2025, grant income was $1.959 million, compared to $0 in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Tonix Pharmaceuticals Holding Corp. is prioritizing the advancement of TNX-102 SL for the management of fibromyalgia, with a PDUFA goal date of August 15, 2025, for marketing authorization. The company is also developing TNX-102 SL for acute stress reaction and acute stress disorder, with topline results expected in the second half of 2026.
-   **Non-Core Business**: The company is developing TNX-1500 for the prevention of allograft rejection and autoimmune diseases, and TNX-1700 for gastric and colorectal cancers. Additionally, TNX-801 and TNX-4200 are being developed for infectious diseases, with a contract from the DoD for up to $34 million over five years to develop TNX-4200.

### Related Stocks

- [TNXP.US - Tonix Pharma](https://longbridge.com/en/quote/TNXP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Tonix Pharma 公布投资者演示，重点介绍 FDA 批准和研发管线的进展 | Tonix Pharmaceuticals Holding Corp. 发布了一份投资者演示文稿，详细介绍了其业务和临床活动。该公司报告现金为 1.9 亿美元，无债务，现金流可持续到 2027 年第一季度。它拥有三款获得 FDA 批准的产品 | [Link](https://longbridge.com/en/news/272109130.md) |
| Tonix Pharma 在 2000 万美元直接股票交易后股价上涨 | Tonix Pharmaceuticals (TNXP) 的股票在盘前交易中上涨了 0.9%，至 16.40 美元，此前该公司向 Steven Cohen 的投资公司 Point72 进行了 2000 万美元的注册直接发行普通股和预先融资的 | [Link](https://longbridge.com/en/news/270999773.md) |
| Tonix Pharma 发布了关于莱姆病的单克隆抗体预防数据 | Tonix 医药控股公司发布了一份文件，详细介绍了一种旨在预防莱姆病的新型单克隆抗体。该文件包括流行病学数据、单克隆抗体治疗与疫苗的比较，以及抗体的起效时间和给药信息。完整文件可通过提供的链接访问。此新闻简报由公共技术公司生成，仅供信息参考 | [Link](https://longbridge.com/en/news/271031125.md) |
| Tonix 医药控股公司发布了关于单克隆抗体 TNX-4800 用于预防莱姆病的报告 | Tonix Pharmaceuticals Holding Corp. 发布了一份关于 TNX-4800 的报告，这是一种用于预防莱姆病的单克隆抗体。该文件强调了莱姆病日益严重的流行情况以及单克隆抗体作为预防治疗的潜力。这份由人工智能生成的 | [Link](https://longbridge.com/en/news/270740197.md) |
| Tonix Pharma 宣布进行 2000 万美元的发行，其中包括预先资助的认股权证 | Tonix Pharmaceuticals Holding Corp. 宣布进行一项 2000 万美元的融资，与 Point72 签署了一项证券购买协议，购买 615,025 股普通股，每股价格为 16.26 美元。同时，还发行了相同数量的 | [Link](https://longbridge.com/en/news/270996879.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.